PDCD1 and glioblastoma: By a combination of TIM-3 antibody MBG453 (sabatolimab) and spartalizumab (a PD-1 checkpoint inhibitor) in the treatment of recurrent GBM, the phase 1 NCT03961971 trial is active, but no results have been posted yet (Table 1).